{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Novelli S"],"funding":["Roche Diagnostics","University of Bonn","Government of Bavaria","National Research Fund Luxembourg","French Ministry for Health","German Ministry for Education and Research","German Centre for Infection Research DZIF","University Hospital","European Union’s Horizon 2020","Bavarian State Ministry of Science and the Arts","University of Bielefeld","Mikrogen","Région Ile-de-France","André Losch Foundation","LMU Munich","Accenture","BMW","INSERM","French Ministry for Research","Viramed","Euroimmun","Dr. Box-Betrobox","Dr. Becker MVZ","Drees-Direction de la Recherche, des Etudes, de l’Evaluation et des Statistiques","Munich Police"],"pagination":["e0320196"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12063904"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(5)"],"pubmed_abstract":["<h4>Objectives</h4>We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries.<h4>Methods</h4>Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18-79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated.<h4>Results</h4>The proportion of seroreversion was 0% within the four first mon"],"journal":["PloS one"],"pubmed_title":["Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies."],"pmcid":["PMC12063904"],"funding_grant_id":["14716281","NA","01KI20271","101016167"],"pubmed_authors":["Bulaev D","Barthelemy K","O'Sullivan MP","Kolodkin A","Castelletti N","Hoelscher M","Warszawski J","Reinkemeyer C","Meyer L","Snoeck CJ","Kroidl I","ORCHESTRA Working Group","de Lamballerie X","Manto C","Ghosh S","le Chenadec J","Novelli S","Kruger R","Vaillant M","Priet S","Wieser A","Satagopam V","Rauschenberger A"],"additional_accession":[]},"is_claimable":false,"name":"Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies.","description":"<h4>Objectives</h4>We described waning in anti-SARS-CoV-2 IgG in adult general populations infected during the first wave of the COVID-19 pandemic in 2020 across three European countries.<h4>Methods</h4>Coordinated analyses were conducted separately in three population-based cohorts with complementary follow-up schedules: the KoCo19 (Germany), EpiCov (France), and CON-VINCE (Luxembourg) cohorts. Serological follow-up was based on the anti-SARS-CoV-2 ELISA-S IgG (Euroimmun) assay. We selected all adults aged 18-79 who had a positive serology (IgG optical density (OD) ratio ≥1.1) between February and July 2020, and at least one subsequent IgG measurement within the following 12 months, while still non-vaccinated.<h4>Results</h4>The proportion of seroreversion was 0% within the four first mon","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-02T12:08:58.929Z","creation":"2026-04-18T03:11:05.538Z"},"accession":"S-EPMC12063904","cross_references":{"pubmed":["40344145"],"doi":["10.1371/journal.pone.0320196"]}}